Pharvaris PHVS Stock
Pharvaris Price Chart
Pharvaris PHVS Financial and Trading Overview
| Pharvaris stock price | 30.14 USD |
| Previous Close | 30.16 USD |
| Open | 30 USD |
| Bid | 21.6 USD x 200 |
| Ask | 37.41 USD x 200 |
| Day's Range | 29.02 - 30 USD |
| 52 Week Range | 15.91 - 33.33 USD |
| Volume | 135.39K USD |
| Avg. Volume | 272.72K USD |
| Market Cap | 2.03B USD |
| Beta (5Y Monthly) | -2.335 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.17 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 46.54 USD |
PHVS Valuation Measures
| Enterprise Value | 1.73B USD |
| Trailing P/E | N/A |
| Forward P/E | -10.663623 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 5.963455 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -10.054 |
Trading Information
Pharvaris Stock Price History
| Beta (5Y Monthly) | -2.335 |
| 52-Week Change | 82.89% |
| S&P500 52-Week Change | 27.69% |
| 52 Week High | 33.33 USD |
| 52 Week Low | 15.91 USD |
| 50-Day Moving Average | 28.83 USD |
| 200-Day Moving Average | 25.84 USD |
PHVS Share Statistics
| Avg. Volume (3 month) | 272.72K USD |
| Avg. Daily Volume (10-Days) | 290.49K USD |
| Shares Outstanding | 69.88M |
| Float | 40.09M |
| Short Ratio | 1.6 |
| % Held by Insiders | 6.13% |
| % Held by Institutions | 85.15% |
| Shares Short | 600.65K |
| Short % of Float | 1.04% |
| Short % of Shares Outstanding | 0.85% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -42.31% |
| Return on Equity (ttm) | -73.021% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -171773408 USD |
| Net Income Avi to Common (ttm) | -168559248 USD |
| Diluted EPS (ttm) | -3.16 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 246.96M USD |
| Total Cash Per Share (mrq) | 3.78 USD |
| Total Debt (mrq) | 738.89K USD |
| Total Debt/Equity (mrq) | 0.31 USD |
| Current Ratio (mrq) | 11.241 |
| Book Value Per Share (mrq) | 4.8797216 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -147367984 USD |
| Levered Free Cash Flow (ttm) | -87675840 USD |
Profile of Pharvaris
| Country | United States |
| State | N/A |
| City | Zug |
| Address | Grafenauweg 8 |
| ZIP | 6300 |
| Phone | 31 712036410 |
| Website | https://pharvaris.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 134 |
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
Q&A For Pharvaris Stock
What is a current PHVS stock price?
Pharvaris PHVS stock price today per share is 30.14 USD.
How to purchase Pharvaris stock?
You can buy PHVS shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Pharvaris?
The stock symbol or ticker of Pharvaris is PHVS.
Which industry does the Pharvaris company belong to?
The Pharvaris industry is Biotechnology.
How many shares does Pharvaris have in circulation?
The max supply of Pharvaris shares is 69.88M.
What is Pharvaris Price to Earnings Ratio (PE Ratio)?
Pharvaris PE Ratio is now.
What was Pharvaris earnings per share over the trailing 12 months (TTM)?
Pharvaris EPS is -3.17 USD over the trailing 12 months.
Which sector does the Pharvaris company belong to?
The Pharvaris sector is Healthcare.
Pharvaris PHVS included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 26853.98 USD — |
-0.89
|
8.32B USD — | 26769.16 USD — | 27130.88 USD — | — - | 8.32B USD — |
| US Tech Global Select Market Com NQGS | 13180.97 USD — |
-0.87
|
— — | 13139.79 USD — | 13316.81 USD — | — - | — — |
| US Tech Health Care IXHC | 1133.51 USD — |
+1.54
|
— — | 1113.35 USD — | 1133.95 USD — | — - | — — |
- {{ link.label }} {{link}}